Meridian Bioscience, Inc.
VIVO · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Market Cap | $1,387,698 | $846,791 | $733,095 | $407,112 |
| - Cash | $81,453 | $49,771 | $53,514 | $62,397 |
| + Debt | $30,957 | $65,922 | $70,613 | $75,824 |
| Enterprise Value | $1,337,202 | $862,942 | $750,194 | $420,539 |
| Revenue | $333,018 | $317,896 | $253,667 | $201,014 |
| % Growth | 4.8% | 25.3% | 26.2% | – |
| Gross Profit | $188,356 | $201,148 | $156,248 | $118,325 |
| % Margin | 56.6% | 63.3% | 61.6% | 58.9% |
| EBITDA | $72,017 | $107,615 | $75,492 | $43,466 |
| % Margin | 21.6% | 33.9% | 29.8% | 21.6% |
| Net Income | $42,459 | $71,407 | $46,186 | $24,382 |
| % Margin | 12.7% | 22.5% | 18.2% | 12.1% |
| EPS Diluted | 0.96 | 1.62 | 1.07 | 0.57 |
| % Growth | -40.7% | 51.4% | 87.7% | – |
| Operating Cash Flow | $82,361 | $66,865 | $47,976 | $35,831 |
| Capital Expenditures | -$8,615 | -$18,312 | -$3,299 | -$3,797 |
| Free Cash Flow | $73,746 | $48,553 | $44,677 | $32,034 |